The size of the Cell-Based Assay Market in North America was worth USD 5.17 billion in 2022 and is estimated to be growing at a CAGR of 10.63% to reach USD 8.56 billion by 2027. North America accounted for the largest share in the global cell-based assays market in 2022.
Cellular testing refers to using living cells in experiments to analyze or understand various acceptances of the body's response to an external toxic or therapeutic agent. The pressure for cost-effective and fitting research tools for drug discovery, improvement, manufacture, toxicity testing, ecotoxicology, biosafety, and biocompatibility of cosmetics and chemicals drives elevating interest in cellular assays. Increasing research and approvals for biologics and biosimilar are expanding the use of cell-based assays as a tool to ensure product potency and safety.
The North American cellular assay market is increasingly driven by the widespread application of methodologies in drug discovery applications in drug manufacturing. Applications are significantly enhanced by the rapid increase in the number of chronic disease drugs in various world regions. The prevalence of cardiovascular disease and diabetes is also fuelling the demand for cellular testing. The contours of the North American cellular assay market are being shaped by the increasing demand for more effective drugs for various potentially fatal diseases. The increasingly important role of cell-based assays in the discovery of anticancer drugs is a case in point. The growing role of cellular assays in accelerating the time to market for drugs by pharmaceutical and biotechnology companies is a crucial trend contributing to the North American cellular assay market's rapid advancement. These trials play a critical role in reducing late-stage drug failure.
Besides, the increasing demand for cell-based analytical methodologies in new investigational drugs is a key market trend. A growing number of in vitro drug studies based on cellular assays is driving the market growth. There has been a significant increase in R&D funding from various public and private organizations to develop better and safer drugs. Additionally, technological advancements in cellular assays have allowed researchers to use this technology for drug discovery and toxicology studies. Another essential factor catalyzing the growth of the market is the increasing prevalence of lifestyle-related diseases such as arthritis, diabetes, epilepsy, cancer, cardiovascular disease, etc., which still have significant needs not satisfied and have led to continued investments in R&D. Besides, the increased adoption of cell analysis techniques for high throughput detection methods such as toxicity studies, drug detection, in vitro testing, etc., further energizes this market.
However, the North American cellular assay market's stable growth is challenged by the high cost of assay instruments and the lack of an appropriate regulatory framework for the use of reagents.
COVID-19 is an unparalleled North American public health emergency that has affected nearly all industries, so the long-term effects that are projected will affect industry growth over the forecast period.
This research report on the North America Cell-Based Assay Market has been segmented and sub-segmented into the following categories:
By Type Of Product:
By End Users:
Regionally, the USA is leading the North American cell-based assay market, followed by Canada.
North America dominated the global cell testing market in 2019, owing to positive government initiatives in cancer research investment and funding, booming pharmaceutical industry, economic conditions, and rising business investments. The United States is a significant market nationally in North America due to considerable investments in research facilities. The increasing prevalence of chronic diseases and lifestyle disorders, such as cancer, cardiovascular disorders, diabetes, and neurological disorders, is a significant growth factor. According to the WHO, chronic diseases like heart disease, cancer, and diabetes are the important factors of death and disability in the United States. According to the American Cancer Society, in 2019, there were over 1.8 million new cases of cancer in the United States. Therefore, there is a need to develop new treatment methods that have led to increased approvals for clinical trials for stem cell therapy.
Companies playing a dominant role in the North America Cell-Based Assay Market profiled in this report are Thermo Fisher Scientific Inc., Becton & Dickinson and Company, Merck & Co. Inc., Cell Signalling Technology Inc., PerkinElmer Inc., Danaher Corporation, General Electric Company, Cisbio Bioassays, DiscoveRx, Ametek Inc., Bio-Rad Laboratories, Roche Diagnostics, GE Healthcare, and Promega Corporation.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org